Verrica Pharmaceuticals Inc. - Common Stock (VRCA)

2.9100
+0.0300 (1.04%)
NASDAQ · Last Trade: Nov 20th, 10:20 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close2.880
Open2.880
Bid2.890
Ask3.050
Day's Range2.880 - 2.910
52 Week Range2.770 - 9.821
Volume2,045
Market Cap122.10M
PE Ratio (TTM)-1.265
EPS (TTM)-2.3
Dividend & YieldN/A (N/A)
1 Month Average Volume58,807

Chart

About Verrica Pharmaceuticals Inc. - Common Stock (VRCA)

Verrica Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for dermatological conditions, particularly for skin diseases like warts and other cutaneous manifestations. The company is dedicated to advancing its proprietary product candidates that utilize a unique approach to deliver targeted therapies, aiming to improve patient outcomes and enhance the quality of life for individuals suffering from these conditions. By leveraging its expertise and cutting-edge technology, Verrica is committed to addressing unmet medical needs within the dermatology space. Read More

News & Press Releases

Verrica (VRCA) Q3 2026 Earnings Call Transcriptfool.com
YCANTH sales hit a record while Gorlin syndrome becomes a new target.
Via The Motley Fool · November 13, 2026
Verrica Pharmaceuticals Q3 Earnings Call Highlightsmarketbeat.com
Verrica Pharmaceuticals (NASDAQ:VRCA) reported record quarterly U.S. revenue for its molluscum treatment YCANTH in the third quarter of 2026, even as total revenue fell from a year earlier and its net loss widened. The company also outlined plans to explore its experimental drug VP-315 in patients
Via MarketBeat · November 13, 2026
Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
– Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · November 12, 2026
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
WEST CHESTER, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in London.
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · November 10, 2026
Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentumchartmill.com
Via Chartmill · May 12, 2026
Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
WEST CHESTER, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Thursday, November 12, 2026, to discuss the Company's financial results for the third quarter ending September 30, 2026, and provide a corporate update.
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · November 5, 2026
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
– Company’s achievement of pre-defined revenue, growth and operational milestones increases facility commitment by $15.0 million –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · October 22, 2026
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
– Analysis shows YCANTH achieved complete clearance of molluscum contagiosum approximately 4 times faster than vehicle, regardless of disease duration –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · September 30, 2026
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
– Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · September 10, 2026
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
WEST CHESTER, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 28th Annual Global Investment Conference.
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · September 8, 2026
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
– Per-protocol interim statistical power analysis confirms no additional patients are recommended for full enrollment –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · August 27, 2026
Verrica (VRCA) Q2 2026 Earnings Call Transcriptfool.com
YCANTH dispensed units surged 28% sequentially as the company secured $27.5M in financing.
Via The Motley Fool · August 13, 2026
Verrica Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com
Verrica Pharmaceuticals (NASDAQ:VRCA) reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common warts and announcing a credit facility that management said could extend its cash runway into 2028. C
Via MarketBeat · August 7, 2026
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
– Company reports record demand for YCANTH® as dispensed applicator units grew to 19,626 in Q2 2026, up 28.3% over the previous quarter and 46.1% year-over-year –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · August 6, 2026
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
— Facility will support YCANTH® commercialization, global Phase 3 program for YCANTH® in common warts and general corporate operations — 
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · August 6, 2026
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Thursday, August 6, 2026, to discuss the Company's financial results for the second quarter ending June 30, 2026, and provide a corporate update.
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · July 30, 2026
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced an exclusive distribution, marketing and supply agreement (“the Agreement”) granting Medomie Pharma Ltd. (“Medomie”) rights to seek regulatory approval for and distribute YCANTH® for the treatment of molluscum contagiosum (“molluscum”) in Israel.
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · July 21, 2026
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan –
By Verrica Pharmaceuticals Inc. · Via GlobeNewswire · June 22, 2026
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference.
Verrica (VRCA) Q1 2026 Earnings Transcriptfool.com
Verrica (VRCA) Q1 2026 Earnings Transcript
Via The Motley Fool · May 13, 2026
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ.
Verrica Pharmaceuticals Q1 Earnings Call Highlightsmarketbeat.com
Verrica Pharmaceuticals (NASDAQ:VRCA) reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development programs in common warts and basal cell carcinoma. President and Chief Executive Officer Jayson Rieger sai
Via MarketBeat · May 12, 2026
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed applicator units since launch –
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors 
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 12, 2026, to discuss the Company's financial results for the first quarter ending March 31, 2026, and provide a corporate update.